High-throughput quantification of the anti-leukemia drug STI571 (Gleevec) and its main metabolite (CGP 74588) in human plasma using liquid chromatography-tandem mass spectrometry.
about
Development and validation of a sensitive assay for the quantification of imatinib using LC/LC-MS/MS in human whole blood and cell culture.Efficacy, safety, and pharmacokinetics of imatinib dose escalation to 800 mg/day in patients with advanced gastrointestinal stromal tumors.Method development and validation for the quantification of dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, sorafenib and sunitinib in human plasma by liquid chromatography coupled with tandem mass spectrometry.Effects of imatinib mesylate on the pharmacokinetics of paracetamol (acetaminophen) in Korean patients with chronic myelogenous leukaemia.Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium reportPopulation pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study.Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein.Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial.Candidate-based proteomics in the search for biomarkers of cardiovascular disease.Simultaneous quantification of imatinib and its main metabolite N-demethyl-imatinib in human plasma by liquid chromatography-tandem mass spectrometry and its application to therapeutic drug monitoring in patients with gastrointestinal stromal tumor.Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia.Therapeutic drug monitoring for imatinib: Current status and Indian experience.A lower dosage of imatinib in patients with gastrointestinal stromal tumors with toxicity of the treatment.Label-free absolute quantitation of oligosaccharides using multiple reaction monitoring.Bioanalytical aspects of clinical mass balance studies in oncology.Antineoplastic drugs and their analysis: a state of the art review.Comment on: Determination of serum levels of imatinib mesylate in patients with chronic myeloid leukemia: validation and application of a new analytical method to monitor treatment compliance.Therapeutic drug monitoring and tyrosine kinase inhibitors.Correlation between imatinib pharmacokinetics and clinical response in Japanese patients with chronic-phase chronic myeloid leukemia.Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia.Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles.Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid.Administration of imatinib mesylate in patients with chronic myeloid leukemia with short bowel.Thymidine-phosphorothioate oligonucleotides induce activation and apoptosis of CLL cells independently of CpG motifs or BCL-2 gene interference.Determination of imatinib and its active metabolite N-desmethyl imatinib in human plasma by liquid chromatography/tandem mass spectrometry.Long-term outcome following imatinib therapy for chronic myelogenous leukemia, with assessment of dosage and blood levels: the JALSG CML202 study.Capillary electrophoresis method for plasmatic determination of imatinib mesylate in chronic myeloid leukemia patients.Association of ABCG2 polymorphism with clinical efficacy of imatinib in patients with gastrointestinal stromal tumor.
P2860
Q33466143-F1D9EBAF-94B5-4509-8012-88987A4EFC71Q34339623-CCB09B0F-299B-49E6-9138-C38FFCCCE7A7Q34417423-C54DF670-9CB4-4932-9D73-AFCBA7712B13Q34580581-6E6DF2E1-70BC-4CB3-8390-70F17055B0C6Q35799962-0E9FBCC6-E4ED-4444-9582-73982A95B020Q35827125-0FD1A602-FC04-4EC2-9194-4DFAFA90192BQ35827616-D095BDD7-DB80-40D7-96C8-ED41F2867DEBQ35930616-B9B8A1F2-3F4D-4EDA-A9C3-7A8EAA278055Q35990040-AF1299C5-8B4D-4DA4-8209-AF438393149DQ36407123-32095E4B-0116-484D-8686-23EFE5D16596Q36792630-31D61784-6BAD-43DA-B3DB-DFD2C1592C2CQ37517632-5D1C7916-28E5-4388-9385-5289F0886037Q37606055-088EA63A-6577-4046-8A47-4C16196DC3E2Q37696921-D63DE6F6-3A40-4FC2-BDBD-73E9D12D75A4Q37963912-8D012462-CEF2-4B6E-A525-1EC0A2AEEE1FQ39339684-6F5AD09C-8035-4972-8807-37C45DD8CA07Q41501511-98B3151D-395A-40A4-A891-226F751B6B03Q41846251-E9C1CFCD-7577-45D3-8146-F359ABAE8495Q42845531-9739CE2B-23A5-4BF4-8116-11333CD97273Q42933358-2E5EA83E-FB3D-4111-B592-C3B07046B4D1Q43841175-673A4D54-73AA-4C7E-83F8-A46442EAD0DEQ44163469-E761265B-F087-434C-88FA-184F2FCFC89DQ46047555-95C3880B-FCDF-4028-802F-20013BCFD0C7Q46540346-848D388D-0D6D-4747-B679-2E5AB1947913Q51336894-FCE31809-C68D-416E-B33B-431FB54A4EABQ54527295-42F39F98-24BB-4A47-9290-DF86D792B940Q54578490-E1858C8C-9300-459A-8891-930EDAFDB7EBQ55070104-BD9EED9F-DBA9-49CC-9477-2735F5857BBD
P2860
High-throughput quantification of the anti-leukemia drug STI571 (Gleevec) and its main metabolite (CGP 74588) in human plasma using liquid chromatography-tandem mass spectrometry.
description
2002 nî lūn-bûn
@nan
2002 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մարտին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
High-throughput quantification ...... aphy-tandem mass spectrometry.
@ast
High-throughput quantification ...... aphy-tandem mass spectrometry.
@en
type
label
High-throughput quantification ...... aphy-tandem mass spectrometry.
@ast
High-throughput quantification ...... aphy-tandem mass spectrometry.
@en
prefLabel
High-throughput quantification ...... aphy-tandem mass spectrometry.
@ast
High-throughput quantification ...... aphy-tandem mass spectrometry.
@en
P2093
P1476
High-throughput quantification ...... aphy-tandem mass spectrometry.
@en
P2093
P304
P356
10.1016/S1570-0232(01)00611-0
P577
2002-03-01T00:00:00Z